Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting — Chronic Lymphocytic Leukemia Edition
Featuring an interview with Dr John Allan, including the following topics: • Update on key studies of acalabrutinib in the front-line setting (0:00) • Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11) • Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06) • Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08) • Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49) • Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22) • Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15) • Emerging data with novel Bcl-2 inhibitors (1:11:26) • Evolving data with subcutaneous epcoritamab for patients with Richter’s transformation and CLL (1:14:37) CME information and select publications